- $4.22m
- -$7.05m
- $0.25m
- 13
- 50
- 11
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.45 | ||
| Price to Tang. Book | 0.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -139.56% | ||
| Return on Equity | -113.3% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 0.01 | n/a | n/a | 0.25 | n/a | n/a | -0.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.
Directors
- James Neal CHM
- Matthew Kalnik PRE (58)
- Dane Saglio CEO (63)
- Thomas Hallam CEO
- Stephanie Diaz DRC
- Robert Trenschel DRC
- Don Williams DRC
- Cristina Csimma IND (62)
- Mary Gray IND (68)
- Binxian Wei IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 28th, 2001
- Public Since
- December 20th, 2006
- No. of Shareholders
- 158
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 937,562
- Address
- 7750 El Camino Real, Suite 5200, CARLSBAD, 92009
- Web
- https://palisadebio.com/
- Phone
- +1 8587044900
- Auditors
- BAKER TILLY US LLP
Upcoming Events for PALI
Q2 2024 Palisade Bio Inc Earnings Release
Q3 2024 Palisade Bio Inc Earnings Release
Similar to PALI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Palisade Bio share price?
As of Today at 22:34 UTC, shares in Palisade Bio are trading at $4.81. This share price information is delayed by 15 minutes.
How has the Palisade Bio share price performed this year?
Shares in Palisade Bio last closed at $4.81 and the price had moved by -81.25% over the past 365 days. In terms of relative price strength the Palisade Bio share price has underperformed the S&P500 Index by -85.08% over the past year.
What are the analyst and broker recommendations for Palisade Bio?
The overall consensus recommendation for Palisade Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Palisade Bio dividend yield?
Palisade Bio does not currently pay a dividend.
Does Palisade Bio pay a dividend?
Palisade Bio does not currently pay a dividend.
When does Palisade Bio next pay dividends?
Palisade Bio does not currently pay a dividend.
How do I buy Palisade Bio shares?
To buy shares in Palisade Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Palisade Bio?
As of the previous close price of $4.81, shares in Palisade Bio had a market capitalisation of $4.51m.
Where are Palisade Bio shares listed?
Here are the trading details for Palisade Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PALI
What kind of share is Palisade Bio?
Based on an overall assessment of its quality, value and momentum Palisade Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Palisade Bio share price forecast for 2024?
The analyst consensus target price for shares in Palisade Bio is $33.75. That is 601.66% above the last closing price of $4.81.
Analysts covering Palisade Bio currently have a consensus Earnings Per Share (EPS) forecast of -$11.65 for the next financial year.
What is the trend in the Palisade Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Palisade Bio. Over the past six months, its share price has underperformed the S&P500 Index by -53.15%.
As of the last closing price of $4.81, shares in Palisade Bio were trading -34.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Palisade Bio PE Ratio?
The Palisade Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Palisade Bio?
Palisade Bio's management team is headed by:
- James Neal - CHM
- Matthew Kalnik - PRE
- Dane Saglio - CEO
- Thomas Hallam - CEO
- Stephanie Diaz - DRC
- Robert Trenschel - DRC
- Don Williams - DRC
- Cristina Csimma - IND
- Mary Gray - IND
- Binxian Wei - IND